SRRK Scholar Rock Holding Corporation Stock Quote

SRRK [NASD]

Index	-	P/E	-	EPS (ttm)	-3.59	Insider Own	1.60%	Shs Outstand	37.20M	Perf Week	-17.87%
Market Cap	200.33M	Forward P/E	-	EPS next Y	-4.17	Insider Trans	0.00%	Shs Float	31.35M	Perf Month	-47.42%
Income	-131.80M	PEG	-	EPS next Q	-0.62	Inst Own	93.20%	Short Float	16.18%	Perf Quarter	-69.05%
Sales	18.80M	P/S	10.66	EPS this Y	-27.60%	Inst Trans	0.41%	Short Ratio	10.87	Perf Half Y	-85.15%
Book/sh	4.63	P/B	1.10	EPS next Y	-13.60%	ROA	-40.70%	Target Price	44.40	Perf Year	-81.28%
Cash/sh	6.44	P/C	0.79	EPS next 5Y	-	ROE	-64.60%	52W Range	4.93 - 44.95	Perf YTD	-79.47%
Dividend	-	P/FCF	-	EPS past 5Y	-40.20%	ROI	-58.50%	52W High	-88.21%	Beta	0.64
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	118.40%	Gross Margin	-	52W Low	7.41%	ATR	0.86
Employees	145	Current Ratio	4.10	Sales Q/Q	17.60%	Oper. Margin	-	RSI (14)	31.66	Volatility	17.39% 12.22%
Optionable	Yes	Debt/Eq	0.29	EPS Q/Q	-23.30%	Profit Margin	-	Rel Volume	1.23	Prev Close	5.10
Shortable	Yes	LT Debt/Eq	0.28	Earnings	May 16 AMC	Payout	-	Avg Volume	466.37K	Price	5.30
Recom	2.00	SMA20	-20.86%	SMA50	-47.76%	SMA200	-77.05%	Volume	74,843	Change	3.92%

Mar-23-22

Initiated

H.C. Wainwright

Buy

$24

Dec-22-21

Downgrade

Jefferies

Buy → Hold

$52 → $28

Nov-19-21

Initiated

Piper Sandler

Overweight

$56

Apr-26-21

Resumed

Credit Suisse

Outperform

$65

Jan-11-21

Initiated

Credit Suisse

Outperform

$65

Jan-06-21

Initiated

JP Morgan

Overweight

$59

Mar-12-20

Initiated

Robert W. Baird

Outperform

$35

May-17-22 02:49PM	Muscle disorder biotech to lose 39 employees, chief medical officer American City Business Journals +14.97%
12:33PM	Scholar Rock Shares Jumps On Updating Strategic Priorities Benzinga
May-16-22 04:15PM	Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities Business Wire -6.63%
May-10-22 08:05AM	ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates Zacks +5.34%
Apr-21-22 07:30AM	Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress Business Wire -7.53%
Mar-24-22 09:29AM	Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar? Zacks +9.73%
Mar-22-22 07:30AM	Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting Business Wire +7.36%
Mar-17-22 01:54PM	Bargain Shopping? 2 Strong Buy Stocks That Are Down 50% This Year TipRanks
Mar-14-22 08:32AM	Scholar Rock To Highlight Apitegromab Data From Ambulatory Cohort In Muscular Dystrophy Benzinga -10.12%
Mar-13-22 07:00PM	Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Business Wire
Mar-07-22 08:15AM	Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM	Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress Business Wire
Mar-01-22 03:00PM	Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline Zacks
Feb-25-22 07:30AM	Scholar Rock to Present at Cowens 42nd Annual Health Care Conference Business Wire
Feb-08-22 12:54PM	The past year for Scholar Rock Holding (NASDAQ:SRRK) investors has not been profitable Simply Wall St.
Jan-25-22 08:30AM	Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGF for Immuno-Oncology Drug Development Summit Business Wire
Jan-10-22 07:30AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2022 Business Wire
Jan-04-22 04:01PM	Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire
Nov-30-21 04:05PM	Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Business Wire
Nov-16-21 10:28AM	Notable Scholar Rock Holding Insider Trades $2.8M In Company Stock Benzinga
Nov-12-21 07:05AM	Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B Business Wire
Nov-09-21 09:15AM	Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:05AM	Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress Business Wire
Nov-02-21 04:01PM	Scholar Rock to Present at Upcoming Healthcare Conferences Business Wire
Nov-01-21 03:01PM	Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q3 Earnings Expected to Decline Zacks
Oct-05-21 12:18PM	Scholar Rock Holding Insider Sold $185K In Company Stock Benzinga
Oct-03-21 08:00AM	Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology Business Wire
Sep-30-21 11:45AM	Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting Business Wire +5.33%
Sep-29-21 02:28PM	Is Scholar Rock Holding Corporation (SRRK) A Good Stock To Buy? Insider Monkey
Sep-28-21 04:01PM	Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGF1 Activation Business Wire
Sep-23-21 11:31AM	Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress Business Wire +7.41%
Sep-22-21 04:01PM	Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference Business Wire -9.29%
Aug-17-21 07:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK Newsfile +6.53%
Aug-16-21 04:05PM	Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer Business Wire
Aug-15-21 12:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK ACCESSWIRE
Aug-13-21 10:07PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK GlobeNewswire
Aug-11-21 11:43PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
Aug-10-21 07:15PM	Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:15PM	Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress Business Wire
06:52AM	Scholar Rock Holding (NASDAQ:SRRK) shareholder returns have been solid, earning 173% in 3 years Simply Wall St.
Aug-09-21 08:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK Newsfile
Aug-07-21 02:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK ACCESSWIRE
Aug-05-21 08:21PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK GlobeNewswire +15.58%
04:01PM	Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference Business Wire
Aug-03-21 10:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire -11.85%
07:30AM	Scholar Rock Announces Leadership Change Business Wire
Jul-30-21 03:00PM	Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q2 Earnings Expected to Decline Zacks
Jun-18-21 08:00AM	Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress Business Wire
Jun-11-21 07:30AM	Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting Business Wire +6.57%
Jun-07-21 07:30AM	Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting Business Wire +6.90%
May-27-21 08:01AM	Scholar Rock to Present at Upcoming Healthcare Conferences in June Business Wire
May-24-21 04:05PM	Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy Business Wire
May-19-21 05:05PM	Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting Business Wire
May-13-21 12:11PM	Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:30AM	Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress Business Wire
May-12-21 07:33AM	Does Scholar Rock Holding (NASDAQ:SRRK) Have A Healthy Balance Sheet? Simply Wall St.
May-11-21 04:30PM	Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy Business Wire +5.41%
Apr-29-21 12:34PM	Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q1 Earnings Expected to Decline Zacks
Apr-26-21 04:59PM	Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation Business Wire
Apr-24-21 09:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK GlobeNewswire
Apr-21-21 08:37PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK Newsfile +5.58%
05:22PM	Scholar Rock Stock Shows Market Leadership With Healthy Jump To 83 RS Rating Investor's Business Daily
Apr-19-21 11:17PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
Apr-16-21 10:23PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK ACCESSWIRE
Apr-14-21 11:57PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK GlobeNewswire +6.07%
Apr-13-21 06:56AM	3 Beaten-Down Biotech Stocks: Can They Recover? Motley Fool
06:25AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
Apr-11-21 04:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK PR Newswire
Apr-10-21 08:30AM	Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting Business Wire
Apr-06-21 12:17PM	Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy Benzinga -20.30%
07:48AM	Scholar Rock Reports Apitegromab Data In Spinal Muscular Atrophy Benzinga
07:00AM	Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Business Wire
Mar-22-21 04:20PM	Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology Business Wire
Mar-18-21 04:05PM	Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors Business Wire -6.71%
Mar-17-21 04:05PM	Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy Business Wire
Mar-15-21 08:00AM	Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference Business Wire +5.36%
Mar-09-21 05:45PM	Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue Estimates Zacks +7.88%
04:05PM	Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress Business Wire
Mar-04-21 12:30PM	Analysts Estimate Scholar Rock Holding Corporation (SRRK) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-04-21 04:30PM	Scholar Rock Announces Senior Management Promotions Business Wire
Jan-27-21 08:00AM	Scholar Rock Presents Preclinical Data for SRK-181 at the TGF for Immuno-Oncology Drug Development Summit Business Wire
Jan-11-21 07:30AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2021 Business Wire +5.50%
Jan-04-21 04:01PM	Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-03-20 06:21PM	Nio, Snap Show Rare Chart Pattern, But Are They Buys? Investor's Business Daily -13.23%
Nov-29-20 11:41AM	Do Hedge Funds Love Scholar Rock Holding Corporation (SRRK)? Insider Monkey
Nov-13-20 08:38AM	Earnings Update: Scholar Rock Holding Corporation (NASDAQ:SRRK) Just Reported And Analysts Are Boosting Their Estimates Simply Wall St. -5.96%
Nov-12-20 08:00AM	Scholar Rock to Present at Upcoming Healthcare Conferences Business Wire +8.59%
Nov-09-20 02:47PM	What Percentage Of Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares Do Insiders Own? Simply Wall St.
08:00AM	Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress Business Wire
Nov-04-20 07:24AM	2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now Motley Fool +10.40%
Nov-02-20 04:05PM	Scholar Rock Announces Closing of Public Offering of Common Stock and Prefunded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire +13.78%
Oct-28-20 10:33PM	Scholar Rock Announces Pricing of Public Offering of Common Stock and Prefunded Warrants Business Wire +44.67%
10:24AM	Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More Zacks
Oct-27-20 04:17PM	Scholar Rock Announces Proposed Public Offering of Common Stock Business Wire +118.80%
10:46AM	Why Scholar Rock Stock Is Skyrocketing Today Motley Fool
07:00AM	Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Business Wire
Oct-19-20 07:30AM	Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance Business Wire
Sep-30-20 07:30AM	Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress Business Wire
Sep-09-20 07:30AM	Scholar Rock Announces First Patient Dosed in Part A2 of DRAGON Phase 1 Proof-of-Concept Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy Business Wire +5.08%
Sep-04-20 03:58PM	Here's Why We're Not At All Concerned With Scholar Rock Holding's (NASDAQ:SRRK) Cash Burn Situation Simply Wall St. -5.68%

Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Myles Edward H	Chief Financial Officer	Nov 15	Sale	35.05	4,879	171,006	24,150	Nov 15 09:28 PM
Myles Edward H	Chief Financial Officer	Nov 12	Sale	35.12	49,848	1,750,437	24,150	Nov 15 09:28 PM
Myles Edward H	Chief Financial Officer	Nov 11	Sale	35.20	23,574	829,857	24,150	Nov 15 09:28 PM
FLIER JEFFREY S.	Director	Oct 01	Sale	30.89	6,000	185,329	22,272	Oct 05 08:15 AM
FLIER JEFFREY S.	Director	Sep 20	Sale	34.09	500	17,045	9,013	Sep 21 04:46 PM
FLIER JEFFREY S.	Director	Jul 26	Sale	31.66	6,000	189,954	28,272	Jul 28 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience